US3538214A - Controlled release medicinal tablets - Google Patents

Controlled release medicinal tablets Download PDF

Info

Publication number
US3538214A
US3538214A US3538214DA US3538214A US 3538214 A US3538214 A US 3538214A US 3538214D A US3538214D A US 3538214DA US 3538214 A US3538214 A US 3538214A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
example
tablet
coating
tablets
film
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Gerald P Polli
Clyde E Shoop
Wayne M Grim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme Corp
Original Assignee
Merck Sharp & Dohme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Description

US. Cl. 424-49 3 Claims ABSTRACT OF THE DISCLOSURE A tablet core containing a medicinal agent is coated with a film made up of a Water-insoluble plastic and particles of a material which is chosen for its selective solubility or digestibility in gastro or intestinal fluids. The removal of the latter material by the intended gastro or intestinal fluids results in a membranous or dialytic film through which the medicinal agent slowly leaches out.

RELATED CASES This is a continuation-in-part of U.S. patent application Ser. No. 586,623, filed Oct. 14, 1966, and US. patent application Ser. No. 597,861 filed Nov. 30, 1966 both now abandoned.

PRIOR ART See related cases.

This invention relates to pharmaceutical compositions and particularly to tablet preparations which upon ingestion are capable of controlling the release of the contained medicine or drug over extended periods of time. This invention also involves a process for making these pharmaceutical tablets.

This controlled release of a medicine or drug is important for several reasons. In the first place it serves to provide the body with medication over a long time and thereby eliminates the need for swallowing an ordinary tablet at frequent intervals. The treatment of any disease with a medicine requires a fairly constant high blood titre of the medicine. If the medicine is metabolized or otherwise eliminated quickly from the body it would be necessary to swallow an ordinary tablet quite often to maintain the desired blood level. The controlled release tablet of this invention makes it possible to swallow the tablet at considerably less frequent intervals.

Some medicines have such a narrow therapeutic ratio that slightly moreof it than is necessary to achieve a therapeutic effect, will cause adverse toxic symptoms. If an ordinary tablet is taken, the rapid release of its medical content may cause such a high blood level that undesirable side reactions will occur. The controlled release tablet of this invention prevents the sudden release of a large amount of medicine and thereby prevents the onset of toxic symptoms.

Some medicines are inherently irritating to the alimentary mucosa and their rapid release from the ordinary tablet may cause damage at the loci of concentrations of the medicine. The tablet of the present invention prevents the build-up of such a troublesome concentration.

Tablets have been prepared in the past which will control the release of the contained medicine but they have not been entirely satisfactory. Some of them have been too expensive to make either because of the expensive ingredients or the complicated apparatus or process to make them or they have been too large because of the necessary additives to obtain the delayed release. Other tablets have been unsatisfactory because they have lacked a uniform release time although made in exactly the 1 ited States ate same way. The tablets of the present invention employ inexpensive tableting material and achieve an exceptionally uniform release of the medicine. These tablets can be made of relatively small size. Furthermore the total elapsed drug release time can be varied and established by the practice of this invention.

Another important consideration is that the material which causes the controlled drug release must be physiologically acceptable. It must have no or a negligible toxic effect upon the person. It must be completely eliminated so that even during prolonged use it does not accumulate in a persons tissues.

In accordance with the invention, a tablet containing the drug is made in a conventional manner and to it is applied a coating composition which will form a membranous film through which the drug slowly will be leached out. This slow leaching action will occur because gastro-intestinal fluids can but slowly pass through the coating film to reach the drug in the tablet core and the drug which then becomes dissolved in the gastro-intestinal fluids can but slowly pass out through the coating film and into the stomach and/or intestines. As the film remains substantially intact throughout the time that all the drug is being leached out the escape of the drug is prolonged and the rate of drug administration remains about uniform.

The coating composition is made up of a plastic having a low water vapor permeability such as cellulose acetate, a film modifying agent hereinafter to be described, a solvent such as acetone and, if desired, a plasticizer and/ or a coloring material. The plastic should be insoluble in gastro-intestinal fluids. Suitable plastics in addition to cellulose acetate are ethylcellulose, cellulose nitrate, low water soluble polyvinyl alcohols and the other plastic pharmaceutical coatings.

The film modifying agent mentioned above should be a material which is chosen so that it will be selectively but readily soluble or digestible in either the stomach fluids or in the intestinal fluids so that when it is partially or fully removed from the coating film the plastic which remains is of a membranous or dialytic nature. If it is intended that the medicament be released in the stomach, the film modifying agent must be one that will be removed by the acid conditions of the stomach. On the other hand, if it is intended that the medicament be released in the intestines (i.e. the tablet is to pass through the stomach substantially intact). The film modifying agent must be one that will be removed by the alkaline conditions of the intestines.

For removal in the stomach, suitable film modifying agents are calcium carbonate, calcium phosphates (mono, di, tri), magnesium citrate, magnesium oxide, sodium bicarbonate, potassium bicarbonate, tetraethanolamine, lactose, polyvinyl pyrrolidone and solid polyethylene glycols; they are hereinafter referred to as Table 1 agents. Satisfactory results have been obtained when from about 0.1 to about 30 parts by weight of the plastic substance has been combined with one part by weight of modifying agent. Most satisfactory results have been obtained when from 1 part to 3 parts by weight of the plastic substances have been combined with one part of the modifying agent.

For removal in the intestines, suitable film modifying agents are benzoic acid, propionic acid, sorbic acid, salicyclic acid and cellulose acetate phthalate; they are hereinafter referred to as Table 2 agents. These agents are used in the same relative amounts set forth above for the other film modifying agents.

In addition to acetone, conventional solvents, such as methanol, ethanol and chloroform may be used. The plasticizer may be the conventional ones such as diethyl phthalate, caster oil, propyelne glycol or glycerol, added 3 to the film forming composition to make it less fragile if this is desired.

The film forming composition is applied as a coating to the tablet cores, the amount and coating thickness being dependent upon the desired rate of release of the medicinal agent of the tablet. In practice, it has been found that satisfactory results may be obtained when an average pharmaceutical tablet is coated with from about 5 to about 100 mg. of the novel composition of this invention, although the amounts of the composition involved may be varied in accordance with the medicament employed and the amount of control of release desired by the practitioner hereof.

To apply this coating composition, conventional tablet coating practices are used. This may use a tumbling barrel into which the coating composition is sprayed or it may use the fluidized column technique in which the coating composition is sprayed upwardly through the bed.

Heretofore, it has been the practice to apply an enterictype coating to pharmaceutical tablets to insure nonlesion inducing passage through the stomach. This enteric-type coating resists disintegration by stomach fluids but is fully disintegrated or dissolved by the intestinal fluids on entering and going through the intestine. The present invention obviates the necessity for any such enteric-type coating upon either the stomach or the intestine dissolving film modifying agent membrane of this invention. This is because this novel film resists disintegration by stomach fluids and prevents or delays release of the medicinal agent in the stomach according to the selected intent. It allows slow release of the medicinal agent from the tablet into either the stomach or the intestines depending on the chosen intent, and does not permit a rapid release.

This is because, as stated above, the continuous dialytic film of this invention serves as a membrane to selectively let gastro or intestinal fluids through to reach the tablet core to dissolve the medicinal agent contained therein and to let the dissolved medicinal agent slowly leach outward through this continuous dialytic film and into the gastro or intestinal tract. The dialytic film not only restricts the access of the gastro-intestinal fluids to the medicinal agent of the matrix core, but it moreover serves to position or space the medicinal agent itself away from the gastro-intestinal mucosa so that a large concentration thereof is not permitted to reach a compartively small area of the gastro-intestinal mucosa.

In the practice of this invention, it is possible to provide a final overcoating to improve the appearance, taste or stability of the tablet. This may contain sugar, or a film former in combination with dyes or pigments, or even other medicaments. This latter medicament may for example, be one which is to be administered with the drug in the tablet core but which should not be in contact with each other in the complete tablet. This may be because of the incompatibility of the two or because it is desired that the medicine in the outer coating be released rapidly and that the drug in the core be released slowly.

The following examples are illustrative of compositions of the present invention and are not to be construed as limiting. Examples 1 to 11 inclusive described tablets having coatings which will become a membranous film in the stomach. Examples 12 to 21 inclusive describe tablets having coatings which will become membranous in the intestines after passing intact through the stomach.

EXAMPLE 1 Ingredients for the tablet core: Per tablet, mg. Potassium chloride (granular) 572 Glyoxalated gelatin 572 Stearic acid 6 ,The amounts of potassium chloride and glyoxalated gelatin set forth above are intimately mixed. A portion 18 removed and mixed with the stearic acid. This is then passed through a number 12 sieve and added to the remaining potassium chloride glyoxalated gelatin mixture. The resultant mixture is then slugged, and the slugs are crushed and fed through a Fitzmill fitted with a 2A screen, and the resulting granules are compressed to form tablets having the desired weight of potassium chloride.

Ingredients for the membranous coating: Percent Nitrocellulose 3.0

Calcium carbonate 1.0

Castor oil 1.0 Propylene glycol 1.0

Acetone to 100.0%.

The nitrocellulose is first wetted with a small amount of acetone, and the mixture agitated until all of the nitrocellulose is dispersed. The calcium carbonate is dispersed in some of the acetone, and the caster oil and propylene glycol in the remaining acetone. To the nitrocellulose dispersion the calcium carbonate, castor oil and propylene glycol dispersion is added with stirring. By passing the product through an homogenizer or mill, the incidence of nozzle clogging in the subsequent spraying operation is reduced significantly.

The film coating is applied to the tablet cores by a continuous spraying operation Well known to skilled workers in the art. Eight (8) milligrams of dry coating are applied to each matrix tablet.

EXAMPLE 2 Other examples of the invention involve the substitution for the potassium chloride in Example 1 of other drugs which require a prolonged administration. Potassium chloride is one example of an irritating drug which should slowly be released and other examples such as aspirin are apparent. An example of a drug which should be released over a prolonged period to maintain a blood level for an extended period is an antihistamine such as neoantergan. Other drugs, such as hypotensive, tranquilizers, etc., are obvious.

Furthermore, instead of the tablet forming materials named in Example 1, the core tablets may be made of other conventional materials and be shaped by known methods.

EXAMPLE 3 Following the procedure set forth in Example 1 but substituting an equivalent amount of ethyl cellulose or cellulose acetate for the nitro cellulose, equivalent results are obtained.

EXAMPLE 4 Tablets containing 572 mg. potassium chloride are prepared as described in Example 1.

A film forming composition of the formula: Nitrocellulose 4.0% Polyethylene glycol 400 1.2% Acetone q.s., 100.0%.

is prepared in accordance with the general procedures set forth in Example 1, with the substitution of the different interchanged ingredients hereof. The resultant film coat is applied to the tablets by a continuous spraying operation as in Example 1. Five (5) milligrams of dry coating are applied to each matrix tablet.

EXAMPLE 5 Tablets containing 572 mg. potassium chloride are prepared as described in Example 1.

A coating solution of the formula:

Percent Nitrocellulose 3.0 Castor oil 1.0 Propylene glycol 1.0 Lactose 1.0

Acetone q.s., 100.0%.

is prepared according to the method described in Example 1. This solution is applied to the tablets by a continuous spraying operation. Fifteen milligrams of coating are applied to each matrix tablet.

EXAMPLE 6 Tablets containing 572 mg. potassium chloride are prepared as described in Example 1.

A coating composition of the formula:

Percent Nitrocellulose 3.0 Castor oil 1.0 Propylene glycol 1.0 Magnesium oxide 1.0

Acetone q.s., 100.0%

is prepared according to the method described in Example 5, except that magnesium oxide is substituted for lactose. This solution is applied to the tablets by a continuous spraying operation. Twenty milligrams of coating are applied to each matrix tablet.

EXAMPLE 7 Tablets containing 572 mg. potassium chloride are prepared as described in Example 1.

- A coating solution of the formula:

Percent Nitrocellulose 1.5 Castor oil 0.5 Propylene glycol 0.5 Magnesium oxide 0.5

Acetone q.s., 100.0%

is prepared according to the method described in Example 5. This solution is applied to the tablets by a continuous spraying operation. Twenty milligrams of coating are applied to each tablet core.

EXAMPLE 8 Ingredients for the tablet core: Per tablet, mg. Potassium chloride (granular) 572 Stearic acid 3 The mixture is mixed, granulated and tableted as in conventional practices and the tablet core is coated as in any of the preceding examples.

EXAMPLE 9 Other examples of the invention involve substitution of one or more of the Table 1 agents mentioned above, for the calcium carbonate or magnesium oxide in the above examples.

EXAMPLE 10 To any one of the preceding coated tablets is added as an overcoating, a conventional sugar coating with or without a dye or a pigment. A representative overcoating is the following:

Place the tablets which have been undercoated in a coating pan and apply 2 charges of a gelatin-acacia solu tion and dust with kaolin. Then apply 7 charges of 17 lb. cut syrup and then apply 14 charges of white syrup which contains titanium dioxide. Over this is applied 12 charges of 17 lb. cut syrup. The tablets are trayed up and air dried, after which they are glazed with pharmaceutical glaze trayed up and again air dried.

EXAMPLE 1 1 The overcoating of Example 10 is applied but additionally includes a medicament. For example, with potassium chloride in the internal matrix core, the overcoating could contain hydrochlorothiazide in the amount of mg. or 50 mg. per tablet. The hydrochlorothiazide is mixed and milled with cut syrup and it is applied onto the tablets which have been undercoated, just prior to the charges containing the titanium dioxide.

The titanium dioxide can be replaced with or be supplemented with any other pigment or dye which is pharmaceutically acceptable.

The tablets prepared in accordance with the teachings of Example 1 were tested for effectiveness in simulated gastric fluid and simulated intestinal baths and the results obtained are tabulated below in Table I.

TABLE I Percent drug released time, hrs. Test. fluid 1 1 2 3 1 A=Simulated gastric fluid; B=Sin1u1ated intestinal fluid.

Tablets prepared according to Example 4 tested in the same manner gave the following data:

TABLE II Percent drug released time, hrs. Test fluid 1 1 2 3 4 Wt. of coating, mg.:

1 A=Simulated gastric fluid; B=Simulated intestinal fluid.

The following Examples 12 to 21 inclusive illustrate tablets having coatings which will pass intact through the stomach and become a membranous film in the intestines.

EXAMPLE 12 Ingredients for the tablet core: Per tablet, mg. Potassium chloride (granular) 572 Glyoxalated gelatin 572 Stearic acid 6 Amount per I tablet, Ingredients for the membranous coating Percent mg.

Cellulose acetate- 2. 0 6. 67 Cellulose acetate phthalate Diethyl phthalate Acetone to- The cellulose acetate is first wetted with a small amount of acetone, and the mixture agitated until all of the cellulose acetate is dispersed. The cellulose acetate phthalate is dispersed in some of the acetone, and the diethyl phthalate in the remaining acetone. To the cellulose acetate dispersion the diethyl phthalate solution and the cellulose acetate phthalate solution are added with stirring. By passing the product through a homogenizer or mill, the incidence of nozzle clogging in the subsequent spraying operation is reduced significantly.

The film coating is applied to the tablet cores by a continuous spraying operation well known to skilled workers in the art. Twenty seven (27) milligrams of dry coating are applied to each matrix tablet.

EXAMPLE 13 Other examples of the invention involve the substitution for the potassium chloride in Example 12 of other drugs which require a prolonged administration. Potassium chloride is one example of an irritating drug which should slowly be released and other examples such as aspirin are apparent. An example of a drug which should be released over a prolonged period to maintain a blood level for an extended period is an antihistamine such as neoantergan. Other durgs, such as hypotensive, tranquilizers, etc. are obvious.

Furthermore, instead of the tablet forming materials named in Example 12, the core tablets may be made of other conventional materials and be shaped by known methods.

EXAMPLE 14 Following the procedure set forth in Example 12 but substituting an equivalent amount of ethyl cellulose for the cellulose acetate, equivalent results are obtained.

EXAMPLE 15 Tablets containing 572 mg. potassium chloride are prepared as described in Example 12.

A film forming composition of the formula:

Percent Nitrocellulose 1.5 Castor oil 0.5 Propylene glycol 0.5 Benzoic acid 0.5

Acetone q.s., 100.0%.

is prepared in accordance with the general procedures set forth in Example 12, with the substitution of the different interchanged ingredients hereof. The resultant film coat is applied to the tablets by a continuous spraying operation as in Example 12. Thirty-three milligrams of dry coating are applied to each matrix tablet.

EXAMPLE 16 Tablets containing 572 mg. potassium chloride are prepared as described in Example 12.

A coating solution of the formula:

Percent Nitrocellulose 3.0 Castor oil 1.0 Propylene glycol 1.0 Benzoic acid 1.0

Acetone q.s., 100.0%

is prepared according to the method described in Example 12. This solution is applied to the tablets by a continuous spraying operation. Twenty-seven (27) milligrams of coating are applied to each matrix tablet.

EXAMPLE 17 Tablets containing 572 mg. potassium chloride are prepared as described in Example 12.

A coating composition of the formula:

Percent Nitrocellulose 3.0 Castor oil 1.0 Propylene glycol l 1.0 Cellulose acetate phthalate 'l.0

Acetone q.s., 100.0%.

is prepared according to the method described in Example 16, except that cellulose acetate phthalate is substituted for benzoic acid. This solution is applied to the tablets by a continuous spraying operation. Twenty milligrams of coating are applied to each matrix tablet.

EXAMPLE 18 Tablets containing 572 mg. potassium chloride are prepared as described in Example 12. A coating solution of the formula:

Percent Nitrocellulose 1.5 Castor oil 0.5 Propylene glycol 0.5 Cellulose acetate phthalate 0.5

Acetone q.s., 100.0%.

is prepared according to the method described in Example 16. This solution is applied to the tablets by a continuous spraying operation. Twenty milligrams of coating are applied to each tablet core.

EXAMPLE 19 Ingredients for the tablet core: Per tablet, mg. Potassium chloride (granular) 572 Stearic acid 3 This mixture is mixed, granulated and tableted as in conventional practices and the tablet core is coated as in any of the preceding examples.

EXAMPLE 20 of one or more of the Table 2 agents mentioned above, for the benzoic acid or cellulose acetate phthalate in the above examples.

EXAMPLE 21 lution and dust with kaolin. Then apply 7 charges of 17' lb. cut syrup and then apply 14 charges of white syrup which contains titanium dioxide. Over this is applied 12 charges of 17 lb. cut syrup. The tablets are trayed up and air dried, after which they are glazed with pharma ceutical glaze, trayed up and again air dried.

EXAMPLE 22 The overcoating of Example 21 is applied but it additionally includes a medicament. For example, with potassium chloride in the internal matrix core, the overcoating could contain hydrochlorothiazide in the amount of 25 mg. or 50 mg. per tablet. The hydrochlorothiazide is mixed and milled with cut syrup and it is applied onto the tablets which have been undercoated, just prior to the charges containing the titanium dioxide.

The titanium dioxide can be replaced with or be supplemented with any other pigment or dye which is pharmaceutically acceptable.

The tablets prepared in accordance with the teachings of Example 12 were tested for effectiveness in simulated gastric fluid and simulated intestinal baths and the results obtained are tabulated below in Table III.

TABLE III Percent drug released time, hrs.

1 A=Sin1ulated gastric fluid; B=Simulated intestinal fluid.

Tablets prepared according to Example 19 tested in 1 A=Simulated gastric fluid; B=Simulated intestinal fluid.

What is claimed is: 1. A pharmaceutical tablet consisting of (a) an internal matrix core comprising potassium chloride or other irritating active medicament which is soluble in gastro-intestinal fluids and which is known to be capable of producing lesions of the gastro-in- Other examples of the invention involve substitution 9 testinal mucosa in passing through the stomach and 2. A tablet according to claim 1 in which said coating intestines, particularly when a large concentration is l to 3 parts by weight of said plastic substance and 1 thereof is permitted to reach a comparatively small part film modifying agent. area of the gastro-intestinal mucosa; and 3. A tablet according to claim 1 in which hydrochloro- (b) a coating on said core which comprises an intimate mixture of from 0.1 to 30 parts by weight of a plastic substance and one part by weight of a film modifying t, References Cited (i) said plastic substance being one of low water UNITED STATES PATENTS vapor permeability and which remains substan- 10 thiazide is incorporated in the coating and potassium chloride is in the internal matrix core.

2,881,085 4/1959 Endicott et al. 424-35 XR tlally mtact 1n gastro-lntestrnal fluids and whlch 2,887,440 5/1959 Greminger et a1 424 35 is selected from the group consisting of cellulose acetate ethylcellulose cellulose nitrate and 2921883 1/1960 Reese a]! 424 35 XR low water soluble ol vin l alcohols 2928770 3/1960 Bardam 424*35 XR P Y Y 2,971,889 2/1961 Swintosky 424 31 (ii) said film modifying agent being one that will 3 030 273 4/1962 be readily soluble in the stomach fluids and be- 3 039 933 6/1962 z gggg ing selected from the group consisting of mag- 3079303 2/1963 Raff et a1 424 35 XR nesium oxide, magnesium citrate, sodium bicar- 3096248 7/1963 Rudzki 424 35 XR bonate, potassium bicarbonate, tetraethanol- 3112220 11/1963 Heiser z' 424 35 XR amine and lactose in the case of coatings to 3247O66 4/1966 Milosovich 424 35 XR form a membranous film in the stomach,

and one that will be readily soluble in the intesti- SHEP ROSE Primary Examiner nal fluids and being selected from the group consisting of propionic acid and sorbic acid in s CL the case of coatings to pass intact through the stomach and form a membranous film in the 424-20 246 intestines.

US3538214A 1969-04-22 1969-04-22 Controlled release medicinal tablets Expired - Lifetime US3538214A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US81839569 true 1969-04-22 1969-04-22

Publications (1)

Publication Number Publication Date
US3538214A true US3538214A (en) 1970-11-03

Family

ID=25225448

Family Applications (1)

Application Number Title Priority Date Filing Date
US3538214A Expired - Lifetime US3538214A (en) 1969-04-22 1969-04-22 Controlled release medicinal tablets

Country Status (1)

Country Link
US (1) US3538214A (en)

Cited By (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835221A (en) * 1970-03-05 1974-09-10 Hoechst Ag Orally administrable drug dosage form having delayed action
DE2336218A1 (en) * 1973-07-17 1975-02-06 Byk Gulden Lomberg Chem Fab New oral drug form and process for their manufacture
US3917813A (en) * 1973-03-28 1975-11-04 Benzon As Alfred Oral drug preparations
USB524121I5 (en) * 1974-11-15 1976-02-03
US3938515A (en) * 1971-12-20 1976-02-17 Alza Corporation Novel drug permeable wall
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
US3996351A (en) * 1974-02-13 1976-12-07 Klaus Bauer Process for orally increasing the blood calcium level of animals
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4056609A (en) * 1976-01-28 1977-11-01 Gunn, Kirchubel & Miller Article for diagnosis of achlorhydria
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US4127650A (en) * 1975-03-31 1978-11-28 William H. Rorer, Inc. Medicinal simethicone containing composition and its method of production
US4140756A (en) * 1976-06-10 1979-02-20 Mead Johnson & Company Film-coated matrix core tablet
US4153677A (en) * 1978-05-18 1979-05-08 Sterling Drug Inc. Controlled-release composition
US4155993A (en) * 1977-01-13 1979-05-22 Lipha, Lyonnaise Industrielle Pharmaceutique Prolonged-release pharmaceutical compositions for oral administration, their methods of making and use
FR2444460A1 (en) * 1978-12-22 1980-07-18 Panoz Donald Controlled release oral galenical formulation - contains active components in micro-granules prepd. under high compression
US4217898A (en) * 1978-10-23 1980-08-19 Alza Corporation System with microporous reservoir having surface for diffusional delivery of agent
US4229428A (en) * 1977-07-22 1980-10-21 Cherqui Jean S Galenical form of administration of betahistine and its derivatives
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4261971A (en) * 1978-12-05 1981-04-14 Aktiebolaget Hassle Pharmaceutically preparation comprising a cardiac glycoside in combination with a polymer
US4263273A (en) * 1978-12-22 1981-04-21 Aktiebolaget Astra Pharmaceutical preparation comprising a cardiac glycoside with a polymer coating
US4361546A (en) * 1978-07-15 1982-11-30 Boehringer Ingelheim Gmbh Retard form of pharmaceuticals with insoluble porous diffusion coatings
US4367217A (en) * 1980-01-12 1983-01-04 Boehringer Ingelheim Gmbh Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof
EP0106443A2 (en) * 1982-08-13 1984-04-25 Benzon Pharma A/S Pharmaceutical oral-controlled release multiple-units formulation
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4568517A (en) * 1983-08-25 1986-02-04 Barnes-Hind, Inc. Disinfection of contact lenses
EP0171457A1 (en) * 1984-08-17 1986-02-19 The Wellcome Foundation Limited Composition for the controlled discharge of an active ingredient, and its preparation
US4587069A (en) * 1983-10-31 1986-05-06 Twinoak Products, Inc. Process for producing color display means
US4597960A (en) * 1983-04-19 1986-07-01 Cohen Edgar C Microencapsulated astringent hemostatic agents and methods of use
US4609542A (en) * 1978-12-22 1986-09-02 Elan Corporation, P.L.C. New pharmaceutical forms for administration of medicaments by oral route, with programmed release
EP0204476A1 (en) * 1985-05-24 1986-12-10 International Minerals And Chemical Corporation Controlled release delivery system for macromolecules
US4629619A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4629620A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4644031A (en) * 1984-02-15 1987-02-17 Rohm Gmbh Coating for pharmaceutical dosage forms
JPS6256419A (en) * 1982-07-08 1987-03-12 Leo Ab Slow release tablet and manufacture
US4666702A (en) * 1984-04-11 1987-05-19 Thiemann Arzneimittel Gmbh Dosage units for controlled release of active material
US4687660A (en) * 1983-08-16 1987-08-18 Burroughs Wellcome Co. Pharmaceutical delivery system
US4693896A (en) * 1985-10-07 1987-09-15 Fmc Corporation Ethylcellulose-coated, gastric-disintegrable aspirin tablet
US4724148A (en) * 1983-08-31 1988-02-09 Yamanouchi Pharmaceutical Co., Ltd. Amosulalol hydrochloride long acting formulation
US4784851A (en) * 1985-03-18 1988-11-15 Rohwer Gary L Composition for treatment of acidosis in ruminants and method
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US4795644A (en) * 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
US4800084A (en) * 1984-02-01 1989-01-24 Horst Zerbe Pharmaceutical product in the form of a pellet with continuous, delayed medicament substance emission
US4824678A (en) * 1984-09-06 1989-04-25 Aktiebolaget Leo Controlled-release medical preparations
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4863743A (en) * 1985-02-19 1989-09-05 Key Pharmaceuticals, Inc. Controlled release potassium chloride
US4880631A (en) * 1987-09-24 1989-11-14 Merck & Co., Inc. Controlled porosity osmotic pump
GB2218905A (en) * 1988-05-27 1989-11-29 Elan Corp Plc Controlled release potassium chloride tablet formulation
US4886668A (en) * 1987-09-24 1989-12-12 Merck & Co., Inc. Multiparticulate controlled porosity osmotic pump
US4954349A (en) * 1987-09-11 1990-09-04 Ciba-Geigy Corporation Oral magnesium and potassium compositions and use
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US4997658A (en) * 1988-11-21 1991-03-05 Merck & Co., Inc. Method for enhancing the lowering of plasma cholesterol levels
US5008112A (en) * 1985-12-16 1991-04-16 International Minerals & Chem. Corporation Device for the extended delivery of diffusible agents
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5051262A (en) * 1979-12-07 1991-09-24 Elan Corp., P.L.C. Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
US5277916A (en) * 1988-02-01 1994-01-11 F. H. Faulding & Co., Ltd. Tetracycline dosage form
US5376383A (en) * 1988-11-21 1994-12-27 Merck & Co., Inc. Method for enhancing the lowering of plasma-cholesterol levels
US5516527A (en) * 1989-01-12 1996-05-14 Pfizer Inc. Dispensing device powered by hydrogel
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
EP0807433A1 (en) * 1994-12-27 1997-11-19 Kanebo Ltd. Sustained-release preparation
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
EP0840598A1 (en) * 1995-06-06 1998-05-13 Church & Dwight Co., Inc. Alkalinizing potassium salt controlled release preparations
JP2773857B2 (en) 1984-10-26 1998-07-09 アルザ・コーポレーション Colon release system penetration 圧構 adult
DE19728249A1 (en) * 1997-07-02 1999-01-07 Georgios Dr Pandalis Product comprises core and natural resin capsule
US5876752A (en) * 1990-08-07 1999-03-02 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US20020119961A1 (en) * 2000-10-19 2002-08-29 Pfizer Inc. Bridged piperazine derivatives
US20030161874A1 (en) * 1999-02-26 2003-08-28 Boyong Li Controlled release oral dosage form
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
US20040019217A1 (en) * 2002-05-14 2004-01-29 Pfizer Inc. Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making
US20040034034A1 (en) * 2001-10-22 2004-02-19 Blumberg Laura C. Novel piperazine derivatives
US20040049057A1 (en) * 2002-05-14 2004-03-11 Pfizer Inc. Dihydro-furan-2-one derivatives, their intermediates and methods of manufacture
US20040058932A1 (en) * 2000-03-31 2004-03-25 Pfizer Inc. Novel piperazine derivatives
US20040063759A1 (en) * 2002-07-18 2004-04-01 Pfizer Inc. Novel piperidine derivatives
US20040072834A1 (en) * 2002-08-12 2004-04-15 Pfizer Inc. Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040102627A1 (en) * 2002-11-21 2004-05-27 Pfizer Inc. 3-Amino-piperadine derivatives and methods of manufacture
US20040101556A1 (en) * 2002-11-21 2004-05-27 Boyong Li Stable pharmaceutical compositions without a stabilizer
US20040116449A1 (en) * 2002-11-26 2004-06-17 Pfizer Inc Method of treatment of transplant rejection
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
US20040127465A1 (en) * 2002-12-13 2004-07-01 Pfizer Inc Novel phosphorus-containing derivatives
WO2004058270A1 (en) 2002-12-31 2004-07-15 Pfizer Products Inc. 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide derivatives as p2x7-inhibitors for the treatment of inflammatory diseases
US20040176390A1 (en) * 2003-03-04 2004-09-09 Pfizer Inc Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors
US20040180905A1 (en) * 2003-03-11 2004-09-16 Pfizer Inc Novel pyrazine compounds as transforming growth factor (TGF) compounds
US20050013860A1 (en) * 2003-07-15 2005-01-20 Gopi Venkatesh Controlled release potassium chloride tablets
US20050075365A1 (en) * 2003-02-14 2005-04-07 Pfizer, Inc. Novel triazolo-pyridines as anti-inflammatory compounds
US20050113395A1 (en) * 2003-11-25 2005-05-26 Pfizer Inc Method of treatment of atherosclerosis
US20050119275A1 (en) * 2003-06-24 2005-06-02 Pfizer Inc. Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid
WO2005074718A1 (en) * 2004-02-06 2005-08-18 Cosmo Technologies Ltd. Pharmaceutical or dietary compositions based on short-chain fatty acids and complex sugars, for intestinal disorders
US20050250790A1 (en) * 2001-06-20 2005-11-10 Pfizer Inc Novel sulfonic acid derivatives
US7381424B2 (en) 2000-12-05 2008-06-03 Macgregor Alexander Hydrostatic delivery system for controlled delivery of agent
US20080226684A1 (en) * 2007-03-12 2008-09-18 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US20090042795A1 (en) * 2007-06-05 2009-02-12 Pasan Fernando Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation
US20090081265A1 (en) * 2007-03-12 2009-03-26 Board Of Regents, The University Of Texas System Highly porous, recognitive polymer systems
US20090232857A1 (en) * 2007-03-12 2009-09-17 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US20090232858A1 (en) * 2007-03-12 2009-09-17 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US20090275504A1 (en) * 2008-05-05 2009-11-05 Janice Mayne Pcsk9 proteins, fragments thereof and methods of modulating pcsk9 phosphorylation and low density lipoprotein (ldlr) degradation
EP2165708A2 (en) 2002-09-18 2010-03-24 Pfizer Products Inc. New pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2010088544A1 (en) 2009-01-30 2010-08-05 Rutgers, The State University Of New Jersey Methods to treat cancer
USRE41783E1 (en) 1999-12-10 2010-09-28 Pfizer Inc. Pyrrolo[2,3-D]pyrimidine compounds
US20110236485A1 (en) * 2000-02-04 2011-09-29 Depomed, Inc. Shell and core dosage form approaching zero-order drug release
EP2462940A1 (en) 2004-11-02 2012-06-13 Chr. Hansen A/S Stabilized bacteriophage formulations
WO2013037065A1 (en) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
WO2014160401A1 (en) 2013-03-13 2014-10-02 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
WO2015061665A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
US9126993B2 (en) 2011-03-18 2015-09-08 Genzyme Corporation Glucosylceramide synthase inhibitors
WO2016016370A1 (en) 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists
WO2016100456A2 (en) 2014-12-18 2016-06-23 Genzyme Corporation Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes
WO2016139227A1 (en) 2015-03-03 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Fgfr3 antagonists
WO2016145046A1 (en) 2015-03-10 2016-09-15 Genzyme Corporation Methods for treating proteinopathies
WO2018007648A1 (en) 2016-07-08 2018-01-11 INSERM (Institut National de la Santé et de la Recherche Médicale) 4-anilino-quinoline compounds as anti-cancer agents
US9918973B2 (en) 2003-12-11 2018-03-20 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US9925173B2 (en) 2004-04-09 2018-03-27 Acorda Therapeutics, Inc. Methods of using sustained release aminopyridine compositions

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2881085A (en) * 1953-11-09 1959-04-07 Abbott Lab Thin film coating for tablets and the like
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US2971889A (en) * 1958-03-18 1961-02-14 Smith Kline French Lab Press coated enteric tablets and process for preparing them
US3030273A (en) * 1959-09-02 1962-04-17 Abbott Lab Plastic tablet coating
US3039933A (en) * 1957-10-07 1962-06-19 Premo Pharmaceutical Lab Inc Ethyl cellulose-polyethylene glycol tablet matrix
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3112220A (en) * 1960-02-26 1963-11-26 Abbott Lab Method and apparatus for coating particles
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2881085A (en) * 1953-11-09 1959-04-07 Abbott Lab Thin film coating for tablets and the like
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3039933A (en) * 1957-10-07 1962-06-19 Premo Pharmaceutical Lab Inc Ethyl cellulose-polyethylene glycol tablet matrix
US2971889A (en) * 1958-03-18 1961-02-14 Smith Kline French Lab Press coated enteric tablets and process for preparing them
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3030273A (en) * 1959-09-02 1962-04-17 Abbott Lab Plastic tablet coating
US3112220A (en) * 1960-02-26 1963-11-26 Abbott Lab Method and apparatus for coating particles
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet

Cited By (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3835221A (en) * 1970-03-05 1974-09-10 Hoechst Ag Orally administrable drug dosage form having delayed action
US3938515A (en) * 1971-12-20 1976-02-17 Alza Corporation Novel drug permeable wall
US3917813A (en) * 1973-03-28 1975-11-04 Benzon As Alfred Oral drug preparations
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
US4083949A (en) * 1973-07-17 1978-04-11 Byk Gulden Lomberg Chemische Fabrik Gmbh New oral form of medicament and a method for producing it
DE2336218A1 (en) * 1973-07-17 1975-02-06 Byk Gulden Lomberg Chem Fab New oral drug form and process for their manufacture
US3996351A (en) * 1974-02-13 1976-12-07 Klaus Bauer Process for orally increasing the blood calcium level of animals
US3982536A (en) * 1974-11-15 1976-09-28 Minnesota Mining And Manufacturing Company Ballistic inoculation of animals and projectile therefor
USB524121I5 (en) * 1974-11-15 1976-02-03
US4127650A (en) * 1975-03-31 1978-11-28 William H. Rorer, Inc. Medicinal simethicone containing composition and its method of production
US4056609A (en) * 1976-01-28 1977-11-01 Gunn, Kirchubel & Miller Article for diagnosis of achlorhydria
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4140756A (en) * 1976-06-10 1979-02-20 Mead Johnson & Company Film-coated matrix core tablet
US4155993A (en) * 1977-01-13 1979-05-22 Lipha, Lyonnaise Industrielle Pharmaceutique Prolonged-release pharmaceutical compositions for oral administration, their methods of making and use
US4229428A (en) * 1977-07-22 1980-10-21 Cherqui Jean S Galenical form of administration of betahistine and its derivatives
US4153677A (en) * 1978-05-18 1979-05-08 Sterling Drug Inc. Controlled-release composition
US4361546A (en) * 1978-07-15 1982-11-30 Boehringer Ingelheim Gmbh Retard form of pharmaceuticals with insoluble porous diffusion coatings
US4459279A (en) * 1978-07-15 1984-07-10 Boehringer Ingelheim Gmbh Retard form of pharmaceuticals with insoluble porous diffusion coatings
US4217898A (en) * 1978-10-23 1980-08-19 Alza Corporation System with microporous reservoir having surface for diffusional delivery of agent
US4261971A (en) * 1978-12-05 1981-04-14 Aktiebolaget Hassle Pharmaceutically preparation comprising a cardiac glycoside in combination with a polymer
US4263273A (en) * 1978-12-22 1981-04-21 Aktiebolaget Astra Pharmaceutical preparation comprising a cardiac glycoside with a polymer coating
FR2444460A1 (en) * 1978-12-22 1980-07-18 Panoz Donald Controlled release oral galenical formulation - contains active components in micro-granules prepd. under high compression
US4609542A (en) * 1978-12-22 1986-09-02 Elan Corporation, P.L.C. New pharmaceutical forms for administration of medicaments by oral route, with programmed release
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US5051262A (en) * 1979-12-07 1991-09-24 Elan Corp., P.L.C. Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby
US4367217A (en) * 1980-01-12 1983-01-04 Boehringer Ingelheim Gmbh Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof
EP0211991B1 (en) * 1982-07-08 1989-10-25 Ab Leo Substained release tablets and method for preparation thereof
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
JPS6256419A (en) * 1982-07-08 1987-03-12 Leo Ab Slow release tablet and manufacture
JPH0764725B2 (en) 1982-07-08 1995-07-12 ディーアイビー リミテッド We release tablets and a method for manufacturing the same
EP0106443A3 (en) * 1982-08-13 1985-11-27 A/S Alfred Benzon Pharmaceutical oral-controlled release multiple-units formulation
EP0106443A2 (en) * 1982-08-13 1984-04-25 Benzon Pharma A/S Pharmaceutical oral-controlled release multiple-units formulation
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4597960A (en) * 1983-04-19 1986-07-01 Cohen Edgar C Microencapsulated astringent hemostatic agents and methods of use
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4687660A (en) * 1983-08-16 1987-08-18 Burroughs Wellcome Co. Pharmaceutical delivery system
US4568517A (en) * 1983-08-25 1986-02-04 Barnes-Hind, Inc. Disinfection of contact lenses
US4765988A (en) * 1983-08-31 1988-08-23 Yamanouchi Pharmaceutical Co., Ltd. Amosulalol hydrochloride long acting formulations
US4724148A (en) * 1983-08-31 1988-02-09 Yamanouchi Pharmaceutical Co., Ltd. Amosulalol hydrochloride long acting formulation
US4587069A (en) * 1983-10-31 1986-05-06 Twinoak Products, Inc. Process for producing color display means
US4800084A (en) * 1984-02-01 1989-01-24 Horst Zerbe Pharmaceutical product in the form of a pellet with continuous, delayed medicament substance emission
USRE35200E (en) * 1984-02-15 1996-04-02 Rohm Gmbh Coating for pharmaceutical dosage forms
US4644031A (en) * 1984-02-15 1987-02-17 Rohm Gmbh Coating for pharmaceutical dosage forms
US4666702A (en) * 1984-04-11 1987-05-19 Thiemann Arzneimittel Gmbh Dosage units for controlled release of active material
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
EP0171457A1 (en) * 1984-08-17 1986-02-19 The Wellcome Foundation Limited Composition for the controlled discharge of an active ingredient, and its preparation
US4629619A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4629620A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4824678A (en) * 1984-09-06 1989-04-25 Aktiebolaget Leo Controlled-release medical preparations
JP2773857B2 (en) 1984-10-26 1998-07-09 アルザ・コーポレーション Colon release system penetration 圧構 adult
US4863743A (en) * 1985-02-19 1989-09-05 Key Pharmaceuticals, Inc. Controlled release potassium chloride
US4784851A (en) * 1985-03-18 1988-11-15 Rohwer Gary L Composition for treatment of acidosis in ruminants and method
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
EP0204476A1 (en) * 1985-05-24 1986-12-10 International Minerals And Chemical Corporation Controlled release delivery system for macromolecules
US4693896A (en) * 1985-10-07 1987-09-15 Fmc Corporation Ethylcellulose-coated, gastric-disintegrable aspirin tablet
US5008112A (en) * 1985-12-16 1991-04-16 International Minerals & Chem. Corporation Device for the extended delivery of diffusible agents
US4795644A (en) * 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
EP0303853A2 (en) * 1987-08-20 1989-02-22 Eastman Chemical Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
EP0303853A3 (en) * 1987-08-20 1990-11-22 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US4954349A (en) * 1987-09-11 1990-09-04 Ciba-Geigy Corporation Oral magnesium and potassium compositions and use
US4886668A (en) * 1987-09-24 1989-12-12 Merck & Co., Inc. Multiparticulate controlled porosity osmotic pump
US4880631A (en) * 1987-09-24 1989-11-14 Merck & Co., Inc. Controlled porosity osmotic pump
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US5277916A (en) * 1988-02-01 1994-01-11 F. H. Faulding & Co., Ltd. Tetracycline dosage form
US5505962A (en) * 1988-05-27 1996-04-09 Elan Corporation, Plc Controlled release pharmaceutical formulation
GB2218905A (en) * 1988-05-27 1989-11-29 Elan Corp Plc Controlled release potassium chloride tablet formulation
GB2218905B (en) * 1988-05-27 1992-04-29 Elan Corp Plc Controlled release pharmaceutical
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5698220A (en) * 1988-08-30 1997-12-16 Pfizer Inc. Asymmetric membranes in delivery devices
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
US4997658A (en) * 1988-11-21 1991-03-05 Merck & Co., Inc. Method for enhancing the lowering of plasma cholesterol levels
US5376383A (en) * 1988-11-21 1994-12-27 Merck & Co., Inc. Method for enhancing the lowering of plasma-cholesterol levels
US5516527A (en) * 1989-01-12 1996-05-14 Pfizer Inc. Dispensing device powered by hydrogel
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5876752A (en) * 1990-08-07 1999-03-02 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
EP0807433A4 (en) * 1994-12-27 2005-12-28 Akzo Nobel Nv Sustained-release preparation
EP0807433A1 (en) * 1994-12-27 1997-11-19 Kanebo Ltd. Sustained-release preparation
EP0840598A1 (en) * 1995-06-06 1998-05-13 Church & Dwight Co., Inc. Alkalinizing potassium salt controlled release preparations
EP0840598A4 (en) * 1995-06-06 2001-08-29 Church & Dwight Co Inc Alkalinizing potassium salt controlled release preparations
DE19728249A1 (en) * 1997-07-02 1999-01-07 Georgios Dr Pandalis Product comprises core and natural resin capsule
DE19728249C2 (en) * 1997-07-02 2001-05-03 Georgios Pandalis Product containing a core and at least one of a natural resin sheath telescope-type capsule, method for producing a film-coated tablet, soft capsule, hard capsule and use of natural resins
US20050147678A1 (en) * 1999-02-26 2005-07-07 Boyong Li Controlled release oral dosage form
US20030198683A1 (en) * 1999-02-26 2003-10-23 Boyong Li Controlled release oral dosage form
US20030161874A1 (en) * 1999-02-26 2003-08-28 Boyong Li Controlled release oral dosage form
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US8747898B2 (en) 1999-02-26 2014-06-10 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US20100278926A1 (en) * 1999-02-26 2010-11-04 Boyong Li Controlled Release Oral Dosage Form
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6905708B2 (en) 1999-02-26 2005-06-14 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US7771750B2 (en) 1999-02-26 2010-08-10 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
USRE41783E1 (en) 1999-12-10 2010-09-28 Pfizer Inc. Pyrrolo[2,3-D]pyrimidine compounds
US8329215B2 (en) 2000-02-04 2012-12-11 Depomed, Inc. Shell and core dosage form approaching zero-order drug release
US8945619B2 (en) 2000-02-04 2015-02-03 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US20110236485A1 (en) * 2000-02-04 2011-09-29 Depomed, Inc. Shell and core dosage form approaching zero-order drug release
US9597338B2 (en) 2000-02-04 2017-03-21 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US20040058932A1 (en) * 2000-03-31 2004-03-25 Pfizer Inc. Novel piperazine derivatives
US20020119961A1 (en) * 2000-10-19 2002-08-29 Pfizer Inc. Bridged piperazine derivatives
US7381424B2 (en) 2000-12-05 2008-06-03 Macgregor Alexander Hydrostatic delivery system for controlled delivery of agent
US6974817B2 (en) 2001-06-20 2005-12-13 Pfizer Inc. Sulfonic acid derivatives
US20050250790A1 (en) * 2001-06-20 2005-11-10 Pfizer Inc Novel sulfonic acid derivatives
US20040034034A1 (en) * 2001-10-22 2004-02-19 Blumberg Laura C. Novel piperazine derivatives
US7098212B2 (en) 2001-10-22 2006-08-29 Blumberg Laura C Piperazine derivatives
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
US20040049057A1 (en) * 2002-05-14 2004-03-11 Pfizer Inc. Dihydro-furan-2-one derivatives, their intermediates and methods of manufacture
US20040019217A1 (en) * 2002-05-14 2004-01-29 Pfizer Inc. Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making
US20040063759A1 (en) * 2002-07-18 2004-04-01 Pfizer Inc. Novel piperidine derivatives
US20040072834A1 (en) * 2002-08-12 2004-04-15 Pfizer Inc. Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide
EP2165708A2 (en) 2002-09-18 2010-03-24 Pfizer Products Inc. New pyrazole derivatives as transforming growth factor (tgf) inhibitors
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
US20050142195A1 (en) * 2002-11-21 2005-06-30 Boyong Li Stable pharmaceutical compositions without a stabilizer
US20040102627A1 (en) * 2002-11-21 2004-05-27 Pfizer Inc. 3-Amino-piperadine derivatives and methods of manufacture
US6893660B2 (en) 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US7084277B2 (en) 2002-11-21 2006-08-01 Pfizer Inc. 3-Amino-piperidine derivatives and methods of manufacture
US8501227B2 (en) 2002-11-21 2013-08-06 Andrx Pharmaceuticals, Llc Stable pharmaceutical compositions without a stabilizer
US20040101556A1 (en) * 2002-11-21 2004-05-27 Boyong Li Stable pharmaceutical compositions without a stabilizer
US7250420B2 (en) 2002-11-26 2007-07-31 Pfizer Inc. Method of treatment of transplant rejection
US20040116449A1 (en) * 2002-11-26 2004-06-17 Pfizer Inc Method of treatment of transplant rejection
US20040127465A1 (en) * 2002-12-13 2004-07-01 Pfizer Inc Novel phosphorus-containing derivatives
WO2004058270A1 (en) 2002-12-31 2004-07-15 Pfizer Products Inc. 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide derivatives as p2x7-inhibitors for the treatment of inflammatory diseases
US20050075365A1 (en) * 2003-02-14 2005-04-07 Pfizer, Inc. Novel triazolo-pyridines as anti-inflammatory compounds
US7321040B2 (en) 2003-02-14 2008-01-22 Pfizer Inc. Triazolo-pyridines as anti-inflammatory compounds
US20080275235A1 (en) * 2003-03-04 2008-11-06 Pfizer Inc. Novel fused heteroaromatic compounds as transforming growth factor (tgf) inhibitors
US7417041B2 (en) 2003-03-04 2008-08-26 Pfizer Inc. Imidazopyrimidines as transforming growth factor (TGF) inhibitors
US20040176390A1 (en) * 2003-03-04 2004-09-09 Pfizer Inc Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors
US20040180905A1 (en) * 2003-03-11 2004-09-16 Pfizer Inc Novel pyrazine compounds as transforming growth factor (TGF) compounds
WO2004080982A1 (en) 2003-03-11 2004-09-23 Pfizer Products Inc. Pyrazine compounds as transforming growth factor (tgf) inhibitors
US7199123B2 (en) 2003-03-11 2007-04-03 Pfizer Inc. Pyrazine compounds as transforming growth factor (TGF) compounds
US20050119275A1 (en) * 2003-06-24 2005-06-02 Pfizer Inc. Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid
US20080279937A2 (en) * 2003-07-15 2008-11-13 Eurand, Inc. Controlled release potassium chloride tablets
US20050013860A1 (en) * 2003-07-15 2005-01-20 Gopi Venkatesh Controlled release potassium chloride tablets
US7632521B2 (en) 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US20050113395A1 (en) * 2003-11-25 2005-05-26 Pfizer Inc Method of treatment of atherosclerosis
US9918973B2 (en) 2003-12-11 2018-03-20 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
WO2005074718A1 (en) * 2004-02-06 2005-08-18 Cosmo Technologies Ltd. Pharmaceutical or dietary compositions based on short-chain fatty acids and complex sugars, for intestinal disorders
US20070128266A1 (en) * 2004-02-06 2007-06-07 Cosmo Technologies Ltd. Pharmaceutical or dietary compositions based on short-chain fatty acids and complex sugars, for intestinal disorders
US9925173B2 (en) 2004-04-09 2018-03-27 Acorda Therapeutics, Inc. Methods of using sustained release aminopyridine compositions
EP2462940A1 (en) 2004-11-02 2012-06-13 Chr. Hansen A/S Stabilized bacteriophage formulations
US9155703B2 (en) 2007-03-12 2015-10-13 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US20090232857A1 (en) * 2007-03-12 2009-09-17 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US20090081265A1 (en) * 2007-03-12 2009-03-26 Board Of Regents, The University Of Texas System Highly porous, recognitive polymer systems
US20090232858A1 (en) * 2007-03-12 2009-09-17 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US8741316B2 (en) 2007-03-12 2014-06-03 Board Of Regents, The University Of Texas System Highly porous, recognitive polymer systems
US20080226684A1 (en) * 2007-03-12 2008-09-18 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US8771713B2 (en) 2007-03-12 2014-07-08 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US8821899B2 (en) 2007-03-12 2014-09-02 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US20090042795A1 (en) * 2007-06-05 2009-02-12 Pasan Fernando Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
US20090275504A1 (en) * 2008-05-05 2009-11-05 Janice Mayne Pcsk9 proteins, fragments thereof and methods of modulating pcsk9 phosphorylation and low density lipoprotein (ldlr) degradation
WO2010088544A1 (en) 2009-01-30 2010-08-05 Rutgers, The State University Of New Jersey Methods to treat cancer
US9139580B2 (en) 2011-03-18 2015-09-22 Genzyme Corporation Glucosylceramide synthase inhibitors
US9126993B2 (en) 2011-03-18 2015-09-08 Genzyme Corporation Glucosylceramide synthase inhibitors
WO2013037065A1 (en) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
WO2014160401A1 (en) 2013-03-13 2014-10-02 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
WO2015061665A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
WO2016016370A1 (en) 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists
WO2016100456A2 (en) 2014-12-18 2016-06-23 Genzyme Corporation Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes
WO2016139227A1 (en) 2015-03-03 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Fgfr3 antagonists
WO2016145046A1 (en) 2015-03-10 2016-09-15 Genzyme Corporation Methods for treating proteinopathies
WO2018007648A1 (en) 2016-07-08 2018-01-11 INSERM (Institut National de la Santé et de la Recherche Médicale) 4-anilino-quinoline compounds as anti-cancer agents

Similar Documents

Publication Publication Date Title
US3488418A (en) Sustained relief analgesic composition
US6171618B1 (en) Combination dosage form comprising cetirizine and pseudoephedrine
US5807580A (en) Film coated tablet compositions having enhanced disintegration characteristics
US6500459B1 (en) Controlled onset and sustained release dosage forms and the preparation thereof
US6221402B1 (en) Rapidly releasing and taste-masking pharmaceutical dosage form
US4126672A (en) Sustained release pharmaceutical capsules
US5200193A (en) Pharmaceutical sustained release matrix and process
US5576022A (en) Controlled release tacrine drug delivery systems and methods for preparing same
US4427648A (en) Dipyridamole-containing pharmaceutical form
US5188840A (en) Slow-release pharmaceutical agent
US4726951A (en) New pharmaceutical forms for administration of medicaments by oral route, with programmed release
US5277916A (en) Tetracycline dosage form
US2928770A (en) Sustained action pill
US4505890A (en) Controlled release formulation and method
US5004613A (en) Oral sustained release pharmaceutical formulation and process
US5260072A (en) Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
US4140756A (en) Film-coated matrix core tablet
US4713248A (en) Diffusion coated multiple-units dosage form
US4980170A (en) Pharmaceutical formulation as well as a process for its preparation
US5283064A (en) Large intestinal dissociative hard capsules
US5246714A (en) Drug preparation
US6068854A (en) Sol-controlled thermocolloid matrix based on gelatin for oral sustained-release form
EP0247983B1 (en) New pharmaceutical preparation for oral use
US20060057207A1 (en) Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
US5268182A (en) Sustained-release drug dosage units of terazosin